Apomorphine (Apokyn®)

Covered only for the FDA‑approved indication: acute, intermittent treatment of "off" episodes in advanced Parkinson's disease (non‑FDA uses are excluded). Coverage requires current carbidopa/levodopa therapy, documented intolerance or inadequate response to at least one other "off" therapy, prescription by or in consultation with a neurologist, subcutaneous administration with dosing starting at 0.2 mL (2 mg) titratable to 0.6 mL (6 mg), and documentation for up to 12 months.

"Apokyn® (apomorphine) is indicated for the acute, intermittent treatment of hypomobility "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) with advanced Parkinson's dis..."

Sign up to see full coverage criteria, indications, and limitations.